Biotechnology rare diseases Vaccines

New vaccine technology shows promise as a tool to combat the opioid crisis

Researchers with the U.S. Military HIV Research Program at the Walter Reed Army Institute of Research (WRAIR) report that an experimental heroin vaccine induced antibodies that prevented the drug from crossing the blood-brain barrier in mice and rats. The vaccine was co-developed at the National Institute on Drug Abuse (NIDA), part of the National Institutes […]

Biotechnology cancer Cell Therapy Clinical Trials Immunotherapies

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse. The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies […]

Biotechnology cancer rare diseases

Drug combination may improve impact of immunotherapy in head and neck cancer

Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers may have found a way to double down on immunotherapy’s effectiveness. In a paper published in the journal JCI Insights on […]

cancer Clinical Trials Immunotherapies

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (1) Although the 19% improvement in overall survival among […]

Biotechnology Cell Therapy Immunotherapies Infectious Diseases

Immune cells may be key to better allergy, infection therapies

By learning how a recently discovered immune cell works in the body, researchers hope to one day harness the cells to better treat allergies and infections, according to new Cornell University research. Type 1 regulatory (Tr1) cells are a type of regulatory immune cell that help suppress immune responses, including inflammation and tissue damage, but […]

cancer Clinical Trials Immunotherapies

Immune-cell numbers predict response to combination immunotherapy in melanoma

Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco researchers joined by physicians from UCSF Health. The findings provide a novel predictive biomarker to identify patients […]

Biotechnology cancer Immunotherapies

UH Seidman Cancer Center Expert Presents Novel Triple-Negative Breast Cancer Immunotherapy Trial at 2016 San Antonio Breast Cancer Symposium

Meeting focuses on state-of-the-art breast cancer research, including immunotherapeutic approaches A researcher from University Hospitals Seidman Cancer Center discussed his upcoming immunotherapy clinical trial for triple-negative breast cancer at the 2016 San Antonio Breast Cancer Symposium. The annual symposium is the premier meeting for more than 7,500 physicians and scientists dedicated to breast cancer treatment, […]

Biotechnology cancer Immunotherapies

Combination Immune Therapy Shows Promise Against Hodgkin Lymphoma

The combination of two new drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early-phase study. Presented Dec. 5 at the annual meeting of the American Society of Hematology in San Diego, the study […]

cancer Clinical Trials Immunotherapies

Experimental CAR-T Treatment Halted as Two More Patients Die During Clinical Trials

Juno Therapeutics said Wednesday it has suspended a Phase II clinical trial of a cancer drug after two patients suffered cerebral edema earlier this week, leaving one dead and the other not expected to recover. The company’s ‘Rocket’ trial for B cell acute lymphoblastic leukemia is testing a drug it calls JCAR015. These drugs work […]

Biotechnology cancer

T Cell Channel Could Be Targeted to Treat Head and Neck Cancers

 Researchers at the University of Cincinnati (UC) have discovered that an ion channel, active within T cells (white blood cells), could be targeted to reduce the growth of head and neck cancers. This research, which was reported this month in Cancer Research, shows that defective Kv1.3 channels, which regulate calcium ions (Ca2+) presence in T […]

cancer Cell Therapy Immunotherapies

JCAR014 Clinical Data Published In Science Translational Medicine: Patients With Advanced Lymphoma In Remission After T-Cell Therapy

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patient’s own immune cells that are […]